However, while current KDIGO guidelines recommend that Hb be measured at least annually in non-anemic patients with stage 3 CKD and twice a year in those with stage 4–5 CKD (non-dialysis), the optimal frequency of monitoring is not yet known (KDIGO Anemia Work Group 2012). This evidence concerns the gene GSTM1 and anemia.